CMV cell therapy for difficult-to-treat viral infection
Part of Genetic & congenital, Immune system & allergy, Infections clinical trials.
This trial tests an immune cell treatment (CMV-specific cytotoxic T cells) for people with a CMV infection that is not improving despite standard antivirals, or who cannot tolerate them. If eligible, the treatment aims to help the body control the virus after transplant-related immune problems.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a CMV infection that has not improved after a full course of the right antiviral medicines, or you cannot tolerate them
- You recently had a transplant: either bone marrow transplant (HSCT) or a solid organ transplant
- Your blood counts are not too low for this treatment (ANC must be at least 500)
- You can be in the trial physically (performance score above 30%) and can give consent
- You are able and willing to avoid pregnancy during the study (negative pregnancy test if needed)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a special immune-cell treatment made to fight adenovirus in people whose adenovirus infection keeps coming back or won’t improve after transplant. It may help control infection when standard antiviral medicines are not working or can’t be tolerated.
This trial tests an immune therapy made from EBV-targeted T-cells to treat EBV infections that do not improve with standard anti-viral medicines. It may help by strengthening the body’s ability to fight EBV after certain transplants or immune problems.
This trial tests a personalized immune cell treatment (CMV-specific T cells) for people whose CMV (a common herpes virus) persists or comes back after a stem cell transplant. It may help your immune system better control CMV when standard antiviral medicines aren’t fully working or can’t be used.
This trial tests whether adding specially trained immune cells (CTLs) from a related donor to standard treatment helps clear persistent adenovirus or CMV infections after a stem cell transplant. It may be an option if standard antiviral therapy isn't working or causes serious side effects.
This trial tests a treatment using specially grown T-cells (a type of immune cell) to fight certain viruses that won't go away with standard medicines. It is for people who have had a stem cell or organ transplant, or who have a weak immune system, and who are struggling with adenovirus, CMV, or EBV infections.
This trial studies whether directly infusing donor-made immune cells (virus-fighting T-cells) is safe and feasible in people who still have viral infections after a stem cell transplant. It may help your body control infections from adenovirus, CMV, or EBV when standard antiviral treatments aren’t working.
Hear when a new Cytomegalovirus Infections trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.